|
|
| Nomenclature |
|
Symbol:
|
Tg(tetO-BRAF*V600E)29Lc
|
|
Name:
|
transgene insertion 29, Lynda Chin
|
|
MGI ID: |
MGI:3834721 |
|
Synonyms: |
Tet-BRAF* |
|
Transgene:
|
Tg(tetO-BRAF*V600E)29Lc
Location:
unknown
|
|
Transgene
description |
|
Transgene
Type: | |
Transgenic (random, expressed) |
|
Mutation: | |
Insertion |
| |
|
Mutation details: The tetracycline operon was used to drive inducible expression of a human cDNA with nucleotide substitutions that result in the amino acid substitution of glutamic acid for valine at position 600 (V600E). This mutation creates a constitutively active form. Two lines were created (lines 29 and 13). Line 29 was selected as the representative line. (J:144358)
|
|
Phenotypes
|
View phenotypes for all genotypes (concatenated display).
|
|
Disease models
|
|
| Find Mice (IMSR) |
Mouse strains and cell lines available from the
International Mouse Strain Resource
(IMSR)
|
Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available |
|
| References |
|
Original: |
J:144358
Jeong JH et al.,
"BRAF activation initiates but does not maintain invasive prostate adenocarcinoma."
PLoS ONE 2008;3(12):e3949
|
|
All: |
1 reference(s)
|
|
Analysis Tools
